Introduction
============

Over the last 2 decades, there has been renewed interest in understanding the role of aldosterone and its receptor (the mineralocorticoid receptor \[MR\]) in cardiovascular function and disease due to the beneficial effects of pharmacological MR antagonists in patients with heart failure.^[@b1]--[@b3]^

In animal models, pharmacological blockade of MR reverses or prevents the adverse effects of aldosterone on cardiac fibrosis.^[@b4]--[@b5]^ Experimentally, chronic infusion of aldosterone induces cardiac inflammation and fibrosis independently of increase in blood pressure.^[@b4]--[@b5]^ Aldosterone also induces cardiac oxidative stress, mainly through activation of NADPH oxidases.^[@b6]^ Noticeably, coadministration of NaCl is essential in these models: Aldosterone alone is not sufficient to induce cardiac fibrosis.

Beside fibrosis, aldosterone also alters cardiomyocyte calcium channel current,^[@b7]^ impairs the activity of the ryanodine receptor,^[@b8]^ and promotes arrhythmia.^[@b9]^ In contrast to fibrosis and inflammation, the proarrythmogenic properties of aldosterone do not require coadministration of salt or a pathological environment. This suggests that aldosterone alone may establish conditions that sensitize cardiac tissue to other triggers; however, the biological processes activated by aldosterone in the heart in the absence of added sodium are far from being fully understood.

The aim of this study was to identify new aldosterone‐regulated biological processes that might contribute to cardiac diseases. We used an approach consisting of pangenomic analysis of genes regulated in vivo in the mouse heart after administration of a low dose of aldosterone. Treatment duration was short (1 week) to favor the identification of primary aldosterone targets rather than those involved in compensatory or adaptive processes occurring after chronic administration of aldosterone. We report that moderate increase in plasma aldosterone concentration regulates cardiac expression of genes involved in proliferation and promotes proliferation of cardiac endothelial cells (ECs). Moreover, pharmacological MR antagonism prevents endothelial proliferation observed in a rat model of heart failure.

Materials and Methods
=====================

Mice
----

Four‐month‐old male mice (B6D2) purchased from Janvier‐Labs (Le Genest‐Saint‐Isle, France) were used for this study. The use of animals was in accordance with the guidelines of the European Community and approved by our institutional animal care and use committee and thus has been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments. Aldosterone (A9477; Sigma‐Aldrich) was resuspended in ethanol, diluted 10× in saline, then infused (60 μg/kg per day) via osmotic minipumps (Alzet) (before minipump implantation, mice were anesthetized by xylasine or ketamine administration) for 1 week (n=6 to 9 per group) or 4 weeks (n=8 per group), as described previously.^[@b10]^ This allowed a moderate increase in plasma aldosterone levels (5‐fold increase, 2.9 nmol/L versus 0.6 nmol/L in control mice).^[@b10]^ Infusion of the vehicle (ethanol 10% in saline) had no effects on the parameters studied.

Blood Pressure Measurement
--------------------------

Systolic blood pressure was measured by tail‐cuff plethysmography in trained conscious mice using a BP‐2000 Visitech system (Bioseb).

Tissue Sampling
---------------

Hearts were rinsed in cold PBS, weighed, and cut into 2 parts (transversal cut). The apex was frozen for mRNA and protein extraction. The base was immersed in Tissue‐Tek (Sakura Finetek France) and frozen in liquid nitrogen‐cooled isopentane for morphological studies. Kidneys were rinsed in cold PBS and weighed. All samples were frozen in liquid nitrogen and kept at −80°C.

Microarray and Gene Expression Analysis
---------------------------------------

Five mice per group were used to carry out microarray experiments (1 week aldosterone treatment). Total RNA was prepared from ventricle samples with the RNeasy Mini Kit (Qiagen), according to the manufacturer\'s instructions, and its quality was assessed with the 2100 Bioanalyzer (Agilent Technologies). Microarray experiments were carried out using the mouse GE 4x44K v2 microarray kit (Agilent Technologies). Labeling of the RNAs, hybridization (1 animal per array), and scanning of the microarrays were performed according to the manufacturer\'s instructions. Data were analyzed using GeneSpring software (Agilent Technologies). The false discovery rate and fold‐change threshold retained were 1% and ≥1.5, respectively. Quantitative real‐time polymerase chain reaction was carried out, as described previously.^[@b11]^ Primer sequences are listed in [Table 1](#tbl01){ref-type="table"}.

###### 

Primer Sequences

  Genes    Forward Primer              Reverse Primer
  -------- --------------------------- --------------------------
  18S      CGCCGCTAGAGGTGAAATTC        TCTTGGCAAATGCTTTCGC
  Ang1     GAAGGGAACCGAGCCTACTC        ACCACCAACCTCCTGTTAGC
  Birc5    GTGACGCCATCATGGGAGCTCC      AGGCTCGTTCTCGGTAGGGCAG
  Ccnb1    TGATTTTGGAGGAGCCATGGCGCTC   GCACTCTTGCCTGTAGCTCTTCGC
  Cdk1     AGTAACGAGCCGAGCCCAGCA       TCGGCCTTGCCAGAGCGTTTG
  Fgf2     GCCAACCGGTACCTTGCTAT        GTCCCGTTTTGGATCCGAGT
  Icam1    TCCGCTACCATCACCGTGTATTC     TGGCCTCGGAGACATTAGAGAAC
  Mcp1     ATCCCAATGAGTAGGCTGGAGAGC    CAGAAGTGCTTGAGGTGGTTGTG
  Neil3    ACCGCCGTTGTGTTCTCCGA        TGGAGCGCTTGCCATGTCTGC
  Pgf      TCTGCTGGGAACAACTCA ACA      GTGAGACACCTCATCAGGGTAT
  Tnfa     GGGACAGTGACCTGGACTGT        AGTGAATTCGGAAAGCCCATT
  Ubc      AGCCCAGTGTTACCACCAAG        ACCCAAGAACAAGCACAAGG
  Vcam     CTGGGAAGCTGGAACGAAGT        GCCAAACACTTGACCGTGAC
  Vegf‐a   AGCAACATCACCATGCAGATCATGC   TGAACAAGGCTCACAGTGAACGC

Ang1 indicates angiopoietin1; Birc5, Baculoviral IAP repeat containing 5; Ccnb1, cyclin B1; Cdk1, cyclin‐dependent kinase 1; Fgf2, fibroblast growth factor 2; Icam1, intercellular adhesion molecule 1; Mcp1, macrophage chemo‐attractant protein 1; Neil3, Nei like 3; Pgf, placental growth factor; Tnf‐α, tumor necrosis factor α; UBC, ubiquitin; Vcam, vascular cell adhesion molecule 1; VEGF‐a, vascular endothelial growth factor A.

Gene Ontology Analysis
----------------------

Gene ontology (GO) analysis was carried using FunNet^[@b12]^ (<http://www.funnet.info/>). FunNet integrates experimental gene expression data and knowledge about the biological roles of transcripts available in genomic annotation systems. Briefly, FunNet performs functional profiling of gene expression data to identify a set of significant (ie, overrepresented) biological themes characterizing the analyzed transcripts (ie, cellular processes, pathways, and molecular functions in which the analyzed transcripts are involved). The options provided with this type of analysis are related to the gene annotation systems to be used for functional profiling of transcripts and to the type of gene‐enrichment computation performed for GO categories (ie, the 3 main conceptual axes of the GO lattice). The annotation systems currently available in FunNet are those provided by the Gene Ontology Consortium and the Kyoto Encyclopedia of Genes and Genomes.

Gene Network Building
---------------------

The gene network was generated through the use of Ingenuity Pathway Analysis (Ingenuity Systems). A data set containing gene identifiers and corresponding expression values was uploaded into in the application. Each identifier was mapped to its corresponding object in the Ingenuity Knowledge Base. The genes, the expression of which was significantly differentially regulated, are called *network‐eligible molecules* and were overlaid onto a global molecular network developed from information contained in the Ingenuity Knowledge Base. Networks of network‐eligible molecules were then algorithmically generated based on their connectivity.

Immunofluorescence
------------------

Left ventricular frozen 4‐μm sections were stained using primary antibodies against Ki‐67 (ab15580; Abcam), CD31 (550274; BD Pharmigen), phospho‐histone H3 (p‐H3; CS9701; Cell Signaling), vinculin (V9131; Sigma‐Aldrich), FITC‐coupled caveolin 1 (sc894‐FITC; Santa Cruz Biotechnology), α‐smooth muscle actin isoform (ab7817; Abcam), and CD68 (ab53444; Abcam). Briefly, frozen sections were fixed in 4% paraformaldehyde and then washed with PBS Tween 20. Subsequently, sections were blocked with 5% bovine serum albumin for 30 minutes and incubated with the primary antibody overnight at 4°C. After rinsing with PBS, the sections were incubated for 1 hour with the appropriate secondary antibody. ECs and cycling or mitotic nuclei were identified with CD31 (or caveolin 1) and Ki‐67 or p‐H3 antibodies, respectively. Because Ki‐67 and p‐H3 are nuclear antigens and CD31 and caveolin1 are membrane proteins, Ki‐67--positive and p‐H3--positive nuclei are surrounded with CD31 or caveolin 1 staining. Vinculin antibody allowed the identification of cardiomyocyte outlines, whereas α‐smooth muscle actin and CD68 antibodies detected smooth muscle cells and macrophages, respectively. A minimum of 5 fields per section was recorded at ×10 and ×20 using a Leica camera equipped with a fluorescent Leica DMR (Leica Microsystems). The Ki‐67 or p‐H3 index is defined as the number of positive Ki‐67 or p‐H3 nuclei per total nuclei. The numbers of capillaries and positive and total nuclei were determined using ImageJ (version 1.43) software. The capillary density was defined as the number of capillaries per surface unit.

Culture of Human Umbilical Vein Endothelial Cells and Aldosterone Treatment
---------------------------------------------------------------------------

Human umbilical vein ECs were purchased from ScienCell Research Laboratories (code 8000). Cells were grown in collagen‐coated flasks with endothelial basal medium 2 supplemented with endothelial cell growth medium 2 (CC3162; Lonza). For experiments, cells were transferred into 6‐well plates at a confluence of 15%. They were grown in serum‐free medium 24 hours before stimulation. Aldosterone (Sigma‐Aldrich) was initially dissolved in ethanol at a concentration of 10^**−**3^ mol/L. Cells were treated with aldosterone (10^**−**8^ mol/L) or vehicle (containing the same proportion of ethanol as treated cells) for 96 hours. Medium was renewed every 48 hours. To investigate the specificity of action of aldosterone, the MR antagonist spironolactone (S3378; Sigma‐Aldrich) was used (dissolved in ethanol) at the final concentration of 10^−6^ mol/L.

Cell‐Proliferation Assessment
-----------------------------

Cell proliferation was assessed with the quick cell proliferation kit (65475; Biorad). Briefly, this assay is based on the cleavage of the tetrazolium salt WST‐1 to formazan by cellular mitochondrial dehydrogenases. Expansion of viable cell numbers results in an increase in the overall activity of the mitochondrial dehydrogenases in the sample, corresponding to an increase in formazan dye metabolism. The formazan dye produced by the viable cells is measured at an absorbance of 440 nm using a standard multiwell spectrophotometer. Absorbance is directly proportional to the number of cells.

Thoracic Aortic Constriction and Eplerenone Treatment
-----------------------------------------------------

Pressure overload was produced by thoracic aortic constriction, as previously described.^[@b10]^ Briefly, 3‐week‐old male rats (body weight 60±1 g) were anaesthetized with intraperitoneal injection of xylazine (50 mg/kg) and ketamine (100 mg/kg). Left ventricle pressure overload was then produced by coarctation of the ascending thoracic aorta with a partially occluded Weck Hemoclip. The same procedure was performed on sham‐operated animals, but no clip was placed around the aorta. Animals were divided into 4 groups: (1) sham operated (n=5), (2) sham operated plus eplerenone (n=4), (3) pressure‐overloaded rats (n=5), and (4) pressure‐ overloaded rats plus eplerenone (n=6). Animals were kept under identical housing conditions and sacrificed after 3 months. Eplerenone (E6657; Sigma‐Aldrich), a specific MR blocker, was incorporated in food and available ad libitum.

Statistics
----------

The results are reported as mean±SEM. The Shapiro--Wilk and Levene tests were used to analyze normality and variance or homogeneity of residuals, respectively. Statistical analysis was performed by *t* test or Mann--Whitney test. For aldosterone with or without spironolactone treatment on human umbilical vein ECs, we used a 2‐factor ANOVA with repeated‐measure analysis followed by Tukey\'s post hoc test. For the thoracic aortic constriction experiment, the Kruskal--Wallis test was performed. The Holm post hoc test was used to adjust for multiple comparisons. Statistical analysis was performed with SigmaPlot (version 11.0) software. Values of *P*\<0.05 were considered statistically significant.

Results
=======

Cardiac Transcriptome
---------------------

One‐week low‐dose aldosterone infusion without increase in sodium intake did not alter blood pressure, body weight, or heart weight ([Table 2](#tbl02){ref-type="table"}). Transcriptomic analysis was performed on cardiac mRNA isolated from aldosterone‐treated and control mice. Sixty‐five probes corresponding to 60 transcripts (51 upregulated and 9 downregulated) ([Figure 1](#fig01){ref-type="fig"}A and [1](#fig01){ref-type="fig"}B; [Table 3](#tbl03){ref-type="table"}) were differentially hybridized between aldosterone‐treated and control mice (fold change of ≥1.5‐fold and false discovery rate \<1%). The microarray data were confirmed by quantitative polymerase chain reaction ([Figure 1](#fig01){ref-type="fig"}C).

###### 

General Characteristics of Mice

                          1 Week      4 Weeks                 
  ----------------------- ----------- ----------- ----------- -----------
  Body weight, g          27.9±0.4    28.7±0.4    33.9±0.6    32.9±0.2
  Heart weight, mg        132.5±3.1   136.9±3.0   172.3±5.4   176.2±4.1
  Blood pressure, mm Hg   126.1±3.1   127.2±2.4   127.3±2.4   131.6±1.8

Values are Mean±SEM. Aldo indicates aldosterone.

![A, Schematic representation of aldosterone‐regulated genes, as predicted by microarray analysis. Aldosterone (1‐week treatment) regulated 60 genes: 51 were upregulated, and 9 were downregulated (fold change ≥1.5, false discovery rate \<1%). B, Heat map of microarray‐predicted aldosterone‐regulated genes. Genes are classified according to the fold change of the genes. C, Genes tested to validate aldosterone‐regulated genes as predicted by microarrays (top of the panel; control n=5 and aldosterone n=5). The expression of these genes was assessed by quantitative real‐time PCR and confirmed microarray results (bottom of the panel, Ctrl n=6 and Aldo n=9). Statistical analysis was performed using the Mann--Whitney test. Mean±SEM. \**P*\<0.05. PCR indicates polymerase chain reaction.](jah3-4-e001266-g1){#fig01}

###### 

Aldosterone‐Regulated Genes in the Heart

  Gene Symbol     Reg    *P* Value   FC     Description
  --------------- ------ ----------- ------ ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Tcrb‐J          Down   0.0043      1.73   *Mus musculus* rearranged T‐cell receptor beta variable region (Vb17a). \[X61758\]
  Disc1           Down   0.0048      1.74   Disrupted in schizophrenia 1 \[ENSMUST00000122389\]
  Ahcyl2          Down   0.0065      1.81   S‐adenosylhomocysteine hydrolase‐like 2 \[ENSMUST00000150365\]
  LOC101056086    Down   0.0069      1.86   PREDICTED: uncharacterized LOC101056086 (LOC101056086), \[XM_003945428\]
  Clcnka          Down   0.0079      1.90   Chloride channel Ka (Clcnka), TV 1, \[NM_024412\]
  Gm6899          Down   0.007       2.00   Adult male corpora quadrigemina cDNA, RIKEN full‐length enriched library, clone:B230320C11 product:hypothetical protein, full insert sequence. \[AK140159\]
  Dlk1            Down   0.0069      2.03   Delta‐like 1 homolog (Drosophila), TV 1, \[NM_010052\]
  Il1rn           Down   0.0089      2.08   Interleukin 1 receptor antagonist, TV 2, \[NM_001039701\]
  Mid1            Down   0.0047      2.21   Midline 1 \[ENSMUST00000149258\]
  Rab13           Up     0.0069      1.51   Adult male corpora quadrigemina cDNA, RIKEN full‐length enriched library, clone:B230212B15 product:GTP‐binding protein rab13 (fragment) homolog \[Rattus norvegicus\], full insert sequence. \[AK080805\]
  Qpct            Up     0.0024      1.51   Glutaminyl‐peptide cyclotransferase (glutaminyl cyclase), \[NM_027455\]
  Emp1            Up     0.0061      1.55   Epithelial membrane protein 1, \[NM_010128\]
  Adamts9         Up     0.0073      1.55   A disintegrin‐like and metallopeptidase (reprolysin type) with thrombospondin type 1 motif, 9, \[NM_175314\]
  Pole2           Up     0.0049      1.56   Polymerase (DNA directed), epsilon 2 (p59 subunit), \[NM_011133\]
  Trim59          Up     0.0035      1.57   Tripartite motif‐containing 59, \[NM_025863\]
  Lhfpl2          Up     0.0069      1.62   Lipoma HMGIC fusion partner‐like 2, \[NM_172589\]
  Birc5           Up     0.0061      1.62   Baculoviral IAP repeat‐containing 5, TV 1, \[NM_009689\]
  Enpep           Up     0.0047      1.63   Glutamyl aminopeptidase, \[NM_007934\]
  Kif22           Up     0.0069      1.65   Kinesin family member 22, \[NM_145588\]
  Kif23           Up     0.0089      1.68   Kinesin family member 23, \[NM_024245\]
  6430562O15Rik   Up     0.0081      1.69   Adult male olfactory brain cDNA, RIKEN full‐length enriched library, clone:6430562O15 product:unclassifiable, full insert sequence. \[AK032482\]
  4930427A07Rik   Up     0.0047      1.72   RIKEN cDNA 4930427A07 gene, \[NM_134041\]
  Ccnf            Up     0.0049      1.75   Cyclin F, \[NM_007634\]
  Ccnb2           Up     0.0062      1.77   Cyclin B2, \[NM_007630\]
  Mki67           Up     0.0085      1.77   Antigen identified by monoclonal antibody Ki 67, \[NM_001081117\]
  Birc5           Up     0.0057      1.77   Baculoviral IAP repeat‐containing 5, TV 3, \[NM_001012273\]
  Ccnb1           Up     0.0067      1.82   Cyclin B1, \[NM_172301\]
  Kif4            Up     0.0057      1.83   Kinesin family member 4, \[NM_008446\]
  Mki67           Up     0.0083      1.84   Antigen identified by monoclonal antibody Ki 67, \[NM_001081117\]
  Cdca5           Up     0.0024      1.85   Cell division cycle associated 5, \[NM_026410\]
  Spag5           Up     0.0062      1.88   Sperm associated antigen 5, \[NM_017407\]
  Ccnd1           Up     0.0035      1.90   Cyclin D1, \[NM_007631\]
  Ect2            Up     0.0074      1.90   Ect2 oncogene, TV 1, \[NM_007900\]
  Kif11           Up     0.0024      1.92   Kinesin family member 11, \[NM_010615\]
  Anln            Up     0.0073      1.93   Anillin, actin binding protein, \[NM_028390\]
  Tpx2            Up     0.0079      1.93   TPX2, microtubule‐associated protein homolog (*Xenopus laevis*), TV 2, \[NM_028109\]
  Exo1            Up     0.0062      1.93   Exonuclease 1, \[NM_012012\]
  Emid2           Up     0.0065      1.94   EMI domain containing 2 \[ENSMUST00000111103\]
  Birc5           Up     0.0024      1.95   Baculoviral IAP repeat‐containing 5, TV 3, \[NM_001012273\]
  Cdk1            Up     0.0047      1.98   Cyclin‐dependent kinase 1, \[NM_007659\]
  Cenpe           Up     0.0064      2.00   Centromere protein E, \[NM_173762\]
  Mcm6            Up     0.0047      2.01   Minichromosome maintenance deficient 6 (MIS5 homolog, *Saccharomyces pombe*) (*Saccharomyces cerevisiae*), \[NM_008567\]
  Prc1            Up     0.0069      2.05   Protein regulator of cytokinesis 1, \[NM_145150\]
  Kif20b          Up     0.0069      2.06   Kinesin family member 20B, \[NM_183046\]
  Nusap1          Up     0.0057      2.08   Nucleolar and spindle associated protein 1, TV 1, \[NM_133851\]
  Mybl2           Up     0.0073      2.13   Myeloblastosis oncogene‐like 2, \[NM_008652\]
  Iqgap3          Up     0.0065      2.13   IQ motif containing GTPase activating protein 3, \[NM_001033484\]
  Ccna2           Up     0.0047      2.16   Cyclin A2, \[NM_009828\]
  Sgol1           Up     0.0047      2.18   Shugoshin‐like 1 (*Saccharomyces pombe*), \[NM_028232\]
  Kif18b          Up     0.0089      2.27   Kinesin family member 18B, \[NM_197959\]
  Dtl             Up     0.0003      2.28   Denticleless homolog (Drosophila), \[NM_029766\]
  Trmt61b         Up     0.0035      2.28   tRNA methyltransferase 61B, TV 2, non‐coding RNA \[NR_027952\]
  Dscc1           Up     0.0016      2.29   Defective in sister chromatid cohesion 1 homolog (*Saccharomyces cerevisiae*), \[NM_183089\]
  Olfr631         Up     0.0064      2.46   Olfactory receptor 631, \[NM_001271020\]
  Bub1b           Up     0.0003      2.47   Budding uninhibited by benzimidazoles 1 homolog, beta (*Saccharomyces cerevisiae*), \[NM_009773\]
  Lrr1            Up     0.0047      2.59   Leucine rich repeat protein 1, \[NM_001081406\]
  Kntc1           Up     0.0047      2.76   Kinetochore associated 1, \[NM_001042421\]
  Melk            Up     0.0049      2.92   Maternal embryonic leucine zipper kinase, \[NM_010790\]
  Fanci           Up     0.0065      2.95   Fanconi anemia, complementation group I, \[NM_145946\]
  Fam64a          Up     0.0049      2.95   Family with sequence similarity 64, member A, \[NM_144526\]
  Bub1            Up     0.0061      2.96   Budding uninhibited by benzimidazoles 1 homolog (*Saccharomyces cerevisiae*), TV 2, \[NM_009772\]
  Neil3           Up     0.0027      3.36   Nei like 3 (*Escherichia coli*), \[NM_146208\]
  Lgr6            Up     0.0065      6.28   Adult male aorta and vein cDNA, RIKEN full‐length enriched library, clone:A530037C04 product:CDNA FLJ14471 FIS, CLONE MAMMA1001030, WEAKLY SIMILAR TO LUTROPIN‐CHORIOGONADOTROPIC HORMONE RECEPTOR homolog \[*Homo sapiens*\]. \[AK040883\]

Some genes appear more than 1 time because the different probe corresponding to these genes have been differentially hybridized between aldosterone‐treated and control mice. FC indicates absolute fold change; *P,* corrected *P* value; Reg, regulation; TV, transcript variant.

Accession number: for all the genes, accession number provided is the National Center for Biotechnology Information GenBank accession number, except for Disc1, Ahcyl2, Mid1, and Emid2, which is the Ensembl accession number.

Gene Ontology Analysis
----------------------

We then performed a GO analysis of the upregulated transcripts to identify the biological processes modulated by aldosterone (the number of transcripts downregulated was too low to perform a significant GO analysis). The GO analysis was based on National Center for Biotechnology Information Entrez Gene identifier (which allows unambiguous identification of transcripts) in a manner that transcripts identified more than once (with different probe names) did not artificially enrich a GO category. Among the 51 aldosterone‐upregulated transcripts, 43 have at least 1 GO biological process annotation; therefore, the rate of coverage was 84%. Aldosterone‐regulated cardiac transcripts were overrepresented in GO categories involved in cell proliferation (cell cycle, cell division, mitosis) ([Figure 2](#fig02){ref-type="fig"}A). For example, 66% of aldosterone‐regulated transcripts were annotated with the *cell cycle* GO biological process annotation. Only 0.04% of the annotated transcripts on the microarray (494 of 14 021) were marked with this annotation, indicating very significant enrichment of this category (*P*\<0.0001).

![A, Gene ontology analysis of aldosterone‐upregulated genes with FunNet software. Aldosterone‐upregulated genes were overrepresented in gene ontology categories involved in cell cycle, proliferation, and mitosis. B, Ki‐67 and p‐H3 immunolabeling of cardiac sections (4 μm) of aldosterone‐treated and control mice. In blue, DAPI‐stained nuclei; in red, Ki‐67 positive nuclei. C, Cardiac Ki‐67 and p‐H3 index quantification. Aldosterone induced an increase in cardiac Ki‐67 and p‐H3 indexes in mice (control n=6 and aldosterone n=9). D, The network was generated using Ingenuity Pathway Analysis software from the aldosterone‐regulated genes. Cyclin B1 (*Ccnb1*) and cyclin dependent kinase 1 (*Cdk1*) (highlighted in red) were the most connected genes. E, Cardiac expression of *Ccnb1* and *Cdk1* genes was increased by aldosterone. Expression of these genes was assessed by quantitative real‐time polymerase chain reaction (normalized to 18S and ubiquitin C genes) (control n=6 and aldosterone n=9). Statistical analysis was performed by Mann--Whitney test. Mean±SEM. \**P*\<0.05 vs controls. Aldo indicates aldosterone; DAPI, 4′,6‐diamidino‐2‐phenylindole; p‐H3, phospho‐histone H3.](jah3-4-e001266-g2){#fig02}

Cardiac Proliferation Assessment
--------------------------------

We assessed cell proliferation in cardiac sections of aldosterone‐treated (1 week) and control mice, probing Ki‐67 as a marker of cell cycle activity^[@b13]^ and p‐H3 as a marker of mitotic activity^[@b14]^ ([Figure 2](#fig02){ref-type="fig"}B). Absolute numbers of Ki‐67 antigen‐labeled cells were consistently higher than those of p‐H3--labeled cells. Ki‐67 protein is present during all active phases of the cell cycle (G~1~, S, G~2~, and mitosis), whereas histone H3 is phosphorylated only during mitosis.^[@b13]--[@b14]^ Aldosterone increased Ki‐67 index by 300% (*P*\<0.05) ([Figure 2](#fig02){ref-type="fig"}C). Similar variation was observed with p‐H3 cardiac immunostaining ([Figure 2](#fig02){ref-type="fig"}C).

Master Genes
------------

To identify genes possibly involved in aldosterone‐induced cardiac cell proliferation, we proceeded to a network analysis. The network was generated from the aldosterone‐regulated genes through the use of an Ingenuity Pathway Analysis system. Among the 60 aldosterone‐regulated genes, 28 were eligible to build a network based on the Ingenuity Knowledge Base. Among the genes used to build the network, we focused on those interacting with the greatest number of other genes in the cytoplasm---cyclin B1 (*Ccnb1*), with 10 interactions---and the nuclei---cyclin dependent kinase 1 (*Cdk1*), with 16 interactions ([Figure 2](#fig02){ref-type="fig"}D). These genes play crucial roles in cell cycling and proliferation. Consistent with Ki‐67 increased index, quantitative polymerase chain reaction confirmed that cardiac expression of these genes was significantly increased by aldosterone ([Figure 2](#fig02){ref-type="fig"}E).

Identification of the Cycling Cells
-----------------------------------

To identify the cell type that proliferates on aldosterone infusion, we performed double immunostaining of cardiac sections from aldosterone‐treated and control mice. In aldosterone‐treated mice, Ki‐67--positive nuclei were localized around the cardiomyocytes that were delineated by vinculin immunostaining ([Figure 3](#fig03){ref-type="fig"}). Very few Ki‐67--positive nuclei colocalized with the α‐smooth muscle actin (a smooth muscle cell marker) or CD68 (a macrophage marker) ([Figure 3](#fig03){ref-type="fig"}). The majority of Ki‐67--positive nuclei were colocalized within CD31‐positive cells, indicating that most of the activated cells were ECs ([Figure 4](#fig04){ref-type="fig"}A). Similar results were obtained with caveolin 1, another marker of ECs ([Figure 4](#fig04){ref-type="fig"}A). P‐H3 was also colocalized within caveolin 1--positive cells, strengthening our previous observation ([Figure 4](#fig04){ref-type="fig"}A). Caveolin 1 specificity for ECs was assessed by double immunostaining of ECs with CD31 and caveolin 1 ([Figure 4](#fig04){ref-type="fig"}B). We conclude that aldosterone promotes EC proliferation in vivo.

![Double immunolabeling of cardiac sections from aldosterone‐treated mice. Cardiac sections (4 μm) were labeled with anti‐Ki‐67 and anti‐CD68 (A), α‐SMA (B) or vinculin (C) antibodies. Ki‐67--positive nuclei were localized all around cardiomyocytes in the interstitium. Very few Ki‐67--positive nuclei colocalized with α‐SMA or CD68. α‐SMA indicates α‐smooth muscle actin.](jah3-4-e001266-g3){#fig03}

![A, Double immunolabeling of cardiac sections from aldosterone‐treated mice (1 week). Cardiac sections (4 μm) were labeled with anti‐Ki‐67 and either anti‐CD31 or anti‐Cav‐1 antibodies. Sections were also colabeled with anti‐p‐H3 and Cav‐1. A very large fraction of Ki‐67 positive nuclei colocalized within CD31 and Cav‐1--positive cells, indicating that most of the activated cells were endothelial cells. P‐H3--positive nuclei also colocalized within Cav‐1 positive cells. B, Double immunolabeling of cardiac sections. Cardiac sections (4 μm) were labeled with anti‐CD31 and anti‐Cav‐1 antibodies. All CD31 (+) cells are positives for Cav‐1 expression, and all Cav‐1 (+) cells are positives for CD31 expression. Cav‐1 is thus specific for endothelial cells. C, Cardiac expression of proangiogenic genes (angiopoietin1 \[*Ang1*\], fibroblast growth factor 2 \[*Fgf2*\], placental growth factor \[*Pgf*\], and vascular endothelial growth factor A \[*Vegf‐a*\] and pro‐inflammatory tumor necrosis factor α \[*Tnf‐*α\]*,* macrophage chemo‐attractant protein 1 \[*Mcp1*\], vascular cell adhesion molecule 1 \[*Vcam1*\], and intercellular adhesion molecule 1 \[*Icam1*\]) was not increased by aldosterone. Expression of these genes was assessed by Q‐PCR (normalized to 18S and ubiquitin C genes) (control n=6 and aldosterone n=9). Statistical analysis was performed by Mann--Whitney test. Mean±SEM. \**P*\<0.05 vs controls. D, Assessment of endothelial cells (HUVEC) proliferation. HUVEC were treated with 10^−8^ mol/L aldosterone (with or without spironolactone 10^−6^ mol/L) for 48 to 96 hours. Cell number was assessed by measurement of the absorbance of medium at 440 nm after the cleavage of the tetrazolium salt WST‐1 to formazan by viable cells. Aldosterone induces an increase in cell number at 96 hours. This effect is abolished by spironolactone (6 wells per condition). Statistical analysis was performed by 2‐factor ANOVA with repeated measures, followed by Tukey\'s post hoc test. Mean±SEM. \**P*\<0.05 vs untreated cells; ^†^*P*\<0.05 vs spironolactone‐treated cells. Aldo indicates aldosterone; Cav‐1 indicates caveolin 1; Ctrl, control; HUVEC, human umbilical vein endothelial cells; p‐H3, phospho‐histone H3; Q‐PCR, quantitative real‐time polymerase chain reaction; spi, spironolactone.](jah3-4-e001266-g4){#fig04}

Cardiac expression of several proangiogenic growth factors (vascular endothelial growth factor A \[VEGFA\], placental growth factor \[PGF\], angiopoietin 1 \[ANG1\], and fibroblast growth factor 2 \[FGF2\]) was not significantly altered by aldosterone treatment for 1 week ([Figure 4](#fig04){ref-type="fig"}C). Similarly, the expression of proinflammatory molecules (tumor necrosis factor α, macrophage chemoattractant protein 1, intercellular adhesion molecule 1 \[ICAM‐1\], and vascular cell adhesion molecule 1) that have been associated with proangiogenic properties of aldosterone in the retina^[@b15]^ was not altered ([Figure 4](#fig04){ref-type="fig"}C).

Aldosterone induction of EC proliferation was further studied ex vivo in human umbilical vein ECs. Aldosterone (10^−8^ mol/L) enhanced human umbilical vein EC proliferation in a time‐dependent manner. This effect was MR dependent because it was prevented by spironolactone addition ([Figure 4](#fig04){ref-type="fig"}D).

Aldosterone Induces Angiogenesis in the Heart
---------------------------------------------

To study whether increase in EC proliferation was accompanied by angiogenesis, we analyzed capillary density. No modifications were detected after 1 week of aldosterone treatment. Longer treatment (4 weeks) did not alter blood pressure and body weight ([Table 2](#tbl02){ref-type="table"}). The heart was not hypertrophied, but capillary density was significantly increased, albeit to a limited extent (+7%, *P*\<0.05) ([Figure 5](#fig05){ref-type="fig"}A and [5](#fig05){ref-type="fig"}B). The expression of Ccnb1 and Cdk1 was not altered, whereas Ki‐67 index was moderately increased (+38%, *P*\<0.05; less than after 1 week treatment \[+300%\] \[[Figure 2](#fig02){ref-type="fig"}C\]) ([Figure 5](#fig05){ref-type="fig"}C and [5](#fig05){ref-type="fig"}D). Expression of *VegfA* was increased (+40%, *P*\<0.005), whereas expression of *Pgf*,*Ang1*, and *Fgf2* was not ([Figure 5](#fig05){ref-type="fig"}E).

![A, Capillary density. Aldosterone administration did not alter the number of capillaries after 1 week (control n=6 and aldosterone n=9) of treatment. Longer treatment (4 weeks; control n=8 and aldosterone n=8) increased capillary density by 7%. Statistical analysis was performed by Mann--Whitney test. Mean±SEM. \**P*\<0.05 vs corresponding controls. B, Immunolabeling of cardiac sections from untreated and aldosterone‐treated mice following 4 weeks of treatment. Cardiac sections (4 μm) were labeled with anti‐CD31 antibody. C and D, Cardiac cell proliferation. C, Aldosterone induced an increase in cardiac Ki‐67 index in mice after 4 weeks of treatment; however, cardiac expression of cyclin B1 (*Ccnb1*) and cyclin dependant kinase 1 (*Cdk1*) genes was not increased (control n=8 and aldosterone n=8). Statistical analysis was performed by Mann--Whitney test. Mean±SEM. \**P*\<0.05 vs controls. D, Ki‐67 immunolabeling of cardiac sections (4 μm) of untreated and aldosterone‐treated mice (4 weeks). In blue, DAPI‐stained nuclei; in red, Ki‐67--positive nuclei. E, Change in transcript expression after 4 weeks aldosterone infusion. Among the proangiogenic factors tested at 1 week (*Ang1*,*Fgf2*,*Pgf*, and *VegfA*), only *VegfA* was increased after 4 weeks of aldosterone treatment (control n=8 and aldosterone n=8). Expression of these genes was assessed by quantitative real‐time polymerase chain reaction (normalized to 18S and ubiquitin C genes). Statistical analysis was performed by Mann--Whitney test. Mean±SEM. \**P*\<0.05 vs controls. *Ang1* indicates angiopoietin1; *Fgf2*, fibroblast growth factor 2; *Pgf*, placental growth factor; Q‐PCR, quantitative real‐time polymerase chain reaction; *Vegf‐a*, vascular endothelial growth factor A.](jah3-4-e001266-g5){#fig05}

Endothelial Cell Proliferation in Heart Failure
-----------------------------------------------

To study whether aldosterone may play a role in cardiac pathologies by promoting EC proliferation, we used a model of heart failure in rat (thoracic aortic constriction) that we characterized in a previous study.^[@b10]^ Thoracic aortic constriction induced an increase in Ki‐67 index (+61%, *P*\<0.05) that was normalized by eplerenone, a specific MR blocker ([Figure 6](#fig06){ref-type="fig"}A). Most of the Ki‐67--positive cells colocalized within caveolin 1--positive cells, indicating that proliferating cells were endothelial ([Figure 6](#fig06){ref-type="fig"}B). Consequently, in this model of heart failure, MR activation participates in proliferation of ECs.

![Cell proliferation in a model of heart failure. A, Ki‐67 immunolabeling of cardiac sections (in blue, DAPI \[4′,6‐diamidino‐2‐phenylindole\]‐stained nuclei; in red, Ki‐67 positive nuclei). TAC induced an increase of Ki‐67 index, an effect reversed by eplerenone (sham n=5, sham plus eplerenone n=4, TAC n=5, and TACplus eplerenone n=6). Statistical analysis was performed by Kruskal--Wallis test. The Holm post hoc test was used to adjust for multiple comparisons. Mean±SEM. \**P*\<0.05 vs sham, ^\#^*P*\<0.05 vs TAC plus eplerenone. B, Double immunolabeling of cardiac sections from rats with TAC. Cardiac sections were labeled with anti‐Ki‐67 and Cav‐1. A very large fraction of Ki‐67--positive nuclei colocalized within Cav‐1 positive cells, indicating that most of the activated cells were endothelial cells. Cav‐1 indicates caveolin 1; TAC, thoracic aortic constriction.](jah3-4-e001266-g6){#fig06}

Discussion
==========

Using a strategy coupling pharmacological and genomic approaches, this study demonstrates that a modest increase in plasma aldosterone concentration that is within the pathophysiological range induces expression of genes involved in cell cycle and promotes cardiac EC proliferation after 1 week and angiogenesis after 4 weeks.

The effects of aldosterone on ECs and angiogenesis are controversial. In mice, aldosterone impairs ECs sprouting from vascular segments.^[@b16]^ In rats, aldosterone decreased the number of circulating endothelial progenitor cells,^[@b17]^ and in patients with hyperaldosteronism, the number of circulating endothelial progenitor cells was inversely correlated with plasma aldosterone concentration.^[@b18]^ Proliferative effects have also been reported in vivo: Aldosterone enhances neovascularization in an experimental model of ischemia,^[@b19]^ prevents capillary rarefaction in a model of type 1 diabetes,^[@b20]^ and stimulates pathological angiogenesis in the retina.^[@b21]^ Ex vivo studies suggest that this apparent paradox may be dose dependent. At high concentrations (10^−5^ to 10^−6^ mol/L, far above pathological conditions), aldosterone attenuated human endothelial progenitor cell proliferation and angiogenesis, whereas lower concentrations (10^−9^ to 10^−8^ mol/L, the biological range) of aldosterone enhanced endothelial progenitor cell and retinal EC proliferation.^[@b18],[@b21]^ Furthermore, at pathophysiological concentrations (10^−9^ to 10^−8^ mol/L), aldosterone increased the formation of tubules by bovine retinal ECs in addition to promoting their proliferation.^[@b21]^ In addition to the dose, in vivo treatment duration and confounding factors (eg, pathologies such as diabetes and heart failure) are parameters that might explain these apparent discrepancies in the literature. Further studies are required for a better understanding of the paradoxical angiogenic properties of aldosterone.

The pathophysiological consequences of aldosterone‐dependent increase in cardiac EC proliferation are unknown. ECs are crucial for heart function by regulating vascular permeability, modulating the diameter of blood vessels in response to hemodynamic and hormonal stimuli, regulating leukocyte recruitment and adhesion, and preventing blood coagulation.^[@b22]^ Several ex vivo studies demonstrated that aldosterone regulates EC functions. In coronary ECs, aldosterone induces the expression of proinflammatory molecules as ICAM‐1 and promotes leukocyte adhesion.^[@b23]^ In human umbilical vein ECs, aldosterone modulates endothelial permeability and endothelial nitric oxide synthase activity.^[@b24]^ We report in this paper that ECs are also sensitive to a low concentration of aldosterone in vivo and that they are targets of aldosterone in the heart. By activating ECs and promoting their proliferation, aldosterone may alter the finely tuned complex balance of interactions of ECs with their immediate environment and thus may sensitize the cardiac tissue to other triggers such as salt, oxidative stress, or increased blood pressure. Furthermore, the pathophysiological consequences of aldosterone‐induced EC proliferation may depend on the environment. In rat, we showed that EC proliferation is increased after thoracic aortic constriction, an effect inhibited by MR blockade. Teekakirikul and collaborators showed that noncardiomyocyte cell proliferation is involved in the cardiac remodeling occurring in hypertrophic cardiomyopathy,^[@b25]^ and although the authors did not address the question of the cell type that proliferates, they speculated on cardiac ECs undergoing endothelial‐to‐mesenchymal transformation, a recognized mechanism involved in cardiac fibrosis.^[@b26]^ EC environment (healthy or pathological) may determine the fate of aldosterone‐activated ECs into neocapillaries or fibroblasts. This hypothesis deserves consideration and needs further investigation.

The mechanisms underlying the proliferative effect of aldosterone on ECs have yet to be established. Aldosterone enhances the expression of proangiogenic factors such as VEGFA^[@b19]^ or placental growth factor, a member of VEGF family.^[@b27]^ In our study, expression of *VegfA* and *Pgf* mRNA and of other proangiogenic factors (Ang1 and Fgf2)^[@b28]^ was not altered after 1 week of treatment, whereas EC proliferation was clearly enhanced (although expression of *VegfA* was increased after 4 weeks, likely to consolidate the newly formed capillaries). This suggests that the primary trigger for aldosterone‐induced EC proliferation may not be through proangiogenic growth factors. Direct activation of ECs should be considered. Indeed, aldosterone acts as a growth‐promoting factor for different cell types (renal mesangial cells^[@b29]^ but also vascular smooth muscle cells^[@b30]^ and cardiac fibroblasts^[@b31]^) by promoting the activation of protein kinase signaling cascades.^[@b30]--[@b31]^ It is possible that aldosterone could directly induce EC proliferation in vivo. Stimulation of inflammation and oxidative stress, which are known to induce angiogenesis,^[@b32]^ is another mechanism that may be involved. Experimentally, the proliferation of vessels in a model of oxygen‐induced retinopathy has been associated with the proinflammatory properties of aldosterone. In this model, TNF‐α, MCP‐1, ICAM‐1, and VCAM‐1 mRNA levels were increased in the retina.^[@b15]^ In our study, we did not find any effect of aldosterone on the expression of these molecules or pro‐oxidative enzymes such as NADPH oxidase (data not shown). It is possible that aldosterone may activate distinct angiogenic pathways according to the vascular microenvironment. We propose that pathological situations may alter the balance between deleterious and beneficial actions of aldosterone, depending on the pathology and the target organ or tissue.

Angiogenesis is a beneficial process in cardiac hypertrophy and ischemic heart diseases.^[@b33]^ In a transgenic model of cardiac hypertrophy, decrease in cardiac function was accompanied by impaired coronary angiogenesis.^[@b34]^ Experimentally and clinically, MR antagonists have proven their efficacy in the treatment of heart failure, whether of ischemic origin or not.^[@b35]^ The beneficial effects of aldosterone blockade are multiple and include antifibrotic and antiarrhythmic properties. Consequently, it is likely that, in these pathological conditions, the deleterious effects of aldosterone overwhelm its positive effects, explaining the beneficial effects of aldosterone antagonists. This may not be the case in all pathological situations. We previously reported that the proangiogenic effects of aldosterone are beneficial in diabetic cardiomyopathy.^[@b20]^ We demonstrated that a moderate increase of cardiac aldosterone (similar to what achieved in the present study) prevents the capillary rarefaction induced by diabetes, an effect blocked by the MR antagonist eplerenone. Spironolactone, another MR antagonist, has been reported to worsen endothelial function in type 2 diabetic patients.^[@b36]^ It is possible that in some pathological situations such as diabetes, such adverse effects of aldosterone antagonists (besides hyperkalemia) need to be taken into account. In contrast, aldosterone‐driven angiogenesis may also be deleterious in pathologies such as cancer, in which angiogenesis is essential for tumor growth and metastasis. Little is known about the involvement of MR and aldosterone in tumoral angiogenesis. In humans, aldosterone‐producing adenoma vascularization is positively associated with aldosterone levels^[@b37]^ whereas eplerenone attenuates hepatocellular carcinoma growth and angiogenesis in mice.^[@b38]^ In contrast, in colorectal cancer, decrease in tumoral MR expression is associated with increased tumoral angiogenesis.^[@b39]^ Further understanding of the role of aldosterone on cardiovascular homeostasis is required to identify potential adverse effects and new therapeutic potential of aldosterone antagonists to allow more efficient and safer use of these drugs.

This study demonstrates, for the first time, that aldosterone induces cardiac EC cycling in vivo in the heart of normal mice. These findings reveal new perspectives on the role played by aldosterone in cardiac physiology and pathology and highlight potential benefits and concerns with regard to pathologies in which beneficial or deleterious angiogenesis is involved.
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